| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2001;72:1179-1182
© 2001 The Society of Thoracic Surgeons
a Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
b Department of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USA
c Department of Pathology and Laboratory Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA
Accepted for publication June 18, 2001.
Address reprint requests to Dr Gal, Department of Pathology and Laboratory Medicine, Emory University Hospital, H-171, 1364 Clifton Rd, NE, Atlanta, GA 30322
e-mail: agal{at}emory.edu
Background. Neuroendocrine tumors of the thymus are rare, histologically diverse neoplasms with an unpredictable clinical behavior. This study provides a useful clinicopathological classification and determines the relevance of specific prognostic factors.
Methods. Ten neuroendocrine tumors of the thymus were analyzed for specific clinical and pathological features. Prognostic factors of these cases and 71 previously published cases were evaluated by Kaplan-Meier survival curves and Cox multivariate hazard model.
Results. There were 7 males and 3 females, with ages ranging from 26 to 77 years. Cases were classified as carcinoid tumor (2), atypical carcinoid tumor (6), and small cell carcinoma (2). An advanced clinical stage was evident in all instances with frequent recurrence (4) and metastases (8), and a short disease-free survival. Overall mortality was 60%. Statistical analysis of current and previously published cases (n = 81 total) revealed that unresectability (p = 0.0001), extent of surgical resection (p = 0.0002), and advanced clinical stage at presentation (p = 0.03) were associated with higher mortality. By multivariate Cox regression analysis, unresectability (p = 0.02) and advanced clinical stage (p = 0.03) were associated with decreased survival.
Conclusions. Neuroendocrine tumors of the thymus can be classified into distinct clinicopathological entities, and specific factors have prognostic relevance.
This article has been cited by other articles:
|
|
 |
|
  S. Ekeblad, A. Sundin, E. T. Janson, S. Welin, D. Granberg, H. Kindmark, K. Dunder, G. Kozlovacki, H. Orlefors, M. Sigurd, et al. Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors Clin. Cancer Res., May 15, 2007; 13(10): 2986 - 2991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Detterbeck and A. M. Parsons Thymic tumors Ann. Thorac. Surg., May 1, 2004; 77(5): 1860 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Filosso, G. M. Actis Dato, E. Ruffini, S. Bretti, F. Ozzello, and M. Mancuso Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): Report of a successful case and review of the literature J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1215 - 1219. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tiffet, A. G. Nicholson, G. Ladas, M. N. Sheppard, and P. Goldstraw A Clinicopathologic Study of 12 Neuroendocrine Tumors Arising in the Thymus Chest, July 1, 2003; 124(1): 141 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chaer, M. G. Massad, A. Evans, N. J. Snow, and A. S. Geha Primary neuroendocrine tumors of the thymus Ann. Thorac. Surg., November 1, 2002; 74(5): 1733 - 1740. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
